Ewing’s tumor

Ewing’s tumor, also known as Ewing sarcoma, is a highly aggressive malignant primary bone tumor arising from primitive neuroectodermal cells. It belongs to the Ewing Sarcoma Family of Tumors (ESFT), which includes tumors originating in bone and soft tissues surrounding bone such as cartilage, muscles, and peripheral nerves.

It primarily affects:

• Children and adolescents (5–20 years)

• Slight male predominance

• Long bones and pelvic bones most commonly involved

Common anatomical sites:

• Femur

• Tibia

• Pelvis

• Ribs

• Humerus

• Mandible and maxilla (rare but clinically significant)

Ewing sarcoma is characterized by rapid growth, early metastasis, and systemic manifestations resembling infection, often leading to delayed diagnosis.

Pathophysiology

Ewing sarcoma results from a specific chromosomal translocation, most commonly:

t(11;22)(q24;q12)t(11;22)(q24;q12)t(11;22)(q24;q12)

This produces the EWSR1–FLI1 fusion gene, which acts as an abnormal transcription factor promoting uncontrolled cellular proliferation.

Biological Mechanisms

1. Genetic Mutation

   • Fusion oncogene activates tumor growth pathways.

   • Suppresses normal cellular differentiation.

2. Bone Marrow Origin

   • Tumor arises from primitive mesenchymal stem cells.

3. Aggressive Local Invasion

   • Rapid destruction of cortical bone.

   • Extension into surrounding soft tissue.

4. Early Hematogenous SpreadCommon metastatic sites:

   • Lungs

   • Bone marrow

   • Other bones

Signs and Symptoms

Local Symptoms

• Progressive localized bone pain

• Pain worse at night or during activity

• Pain not relieved by rest

• Swelling over affected bone

• Warm, tender soft tissue mass

• Reduced joint movement

Systemic Symptoms

• Low-grade fever

• Weight loss

• Fatigue and weakness

• Anemia-related symptoms

Advanced Disease

• Pathological fracture

• Neurological deficit (nerve compression)

• Jaw involvement causing facial asymmetry or paralysis

• Difficulty chewing or speaking (craniofacial cases)

Diagnostic Criteria

Diagnosis requires clinical, radiological, and histological confirmation.

Clinical Criteria

• Painful swelling

• Fever mimicking infection

• Rapid tumor enlargement

• Functional impairment

Radiological Characteristics

• Poorly defined osteolytic lesion

• “Moth-eaten” bone destruction

• Periosteal reaction:

  • Onion-skin appearance

  • Sunburst pattern (occasionally)

Histological Criteria

• Small round blue cells

• High nuclear-to-cytoplasmic ratio

• Positive CD99 immunostaining

• Molecular confirmation of EWSR1 translocation

Investigations

1. Imaging Studies

X-Ray

First-line investigation showing:

• Osteolytic destruction

• Cortical erosion

• Periosteal reaction

Magnetic Resonance Imaging (MRI)

Gold standard for:

• Tumor extent

• Soft tissue involvement

• Neurovascular invasion

Computed Tomography (CT Scan)

Useful for:

• Cortical bone evaluation

• Lung metastasis detection

Bone Scan

Detects skeletal metastases using radioactive tracer.

PET Scan

Assesses:

• Tumor activity

• Treatment response

• Metastatic spread

2. Laboratory Tests

• Complete Blood Count (CBC)

  • Anemia

  • Leukocytosis

• Elevated ESR and LDH (poor prognostic marker)

3. Histopathological Confirmation

Mandatory for diagnosis

Includes:

• Core needle biopsy

• Open biopsy if required

4. Bone Marrow Aspiration & Biopsy

Performed to evaluate marrow metastasis.

Staging

Commonly staged using:

• Enneking staging system

• TNM classification

Categories:

• Localized disease

• Metastatic disease at presentation

Treatment

Management requires multidisciplinary oncology care.

A. Non-Pharmacological Treatment

1. Surgical Management

Primary treatment when feasible.

Procedures:

• Wide local excision

• Limb-sparing surgery (preferred)

• Reconstruction surgery

• Amputation (rare cases)

Goal:

• Complete tumor removal with negative margins.

2. Radiotherapy

Indications:

• Inoperable tumors

• Positive surgical margins

• Poor surgical candidates

• Palliation

Ewing sarcoma is relatively radiosensitive.

B. Pharmacological Treatment

Combination Chemotherapy (Standard of Care)

Given:

• Before surgery (neoadjuvant)

• After surgery (adjuvant)

Common Regimens:

• Vincristine

• Doxorubicin

• Cyclophosphamide

• Ifosfamide

• Etoposide

(VDC/IE protocol widely used)

Chemotherapy significantly improves survival from <10% to >70% in localized disease.

Treatment Phases

1. Neoadjuvant chemotherapy

2. Local control (surgery/radiation)

3. Adjuvant chemotherapy

Complications

• Metastasis

• Growth disturbances in children

• Treatment-related cardiotoxicity

• Secondary malignancies

• Functional disability

Prognosis

Favorable Factors

• Localized disease

• Small tumor size

• Good chemotherapy response

• Younger age

Poor Prognostic Factors

• Metastasis at diagnosis

• Pelvic tumors

• Large tumor volume

• High LDH levels

5-year survival:

• Localized disease: 65–75%

• Metastatic disease: 20–30%

Prevention

There is no known primary prevention because the disease arises from spontaneous genetic mutation.

However:

• Early evaluation of persistent bone pain

• Prompt imaging of unexplained swelling

• Early referral to oncology centers

• Awareness among primary healthcare providers

Early diagnosis greatly improves survival.

Role of Mid-Level Healthcare Providers

Healthcare workers should:

• Suspect malignancy in persistent bone pain >2 weeks

• Avoid repeated treatment as infection without imaging

• Refer urgently for imaging and biopsy

• Monitor chemotherapy complications

• Provide rehabilitation support